Department of Medicine, New York University Grossman School of Medicine, USA.
Department of Human Physiology and Pathophysiology, School of Medicine, University of Warmia and Mazury, Olsztyn, Poland.
Polim Med. 2023 Jul-Dec;53(2):105-110. doi: 10.17219/pim/175544.
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder with largely unknown pathogenesis and no effective cure. It is believed that several, not mutually exclusive mechanisms contribute to the pathogenesis and progression of this disease, including, among others, elevated oxidative stress, excitotoxicity, increased neuroinflammation, and protein aggregation. Receptor for advanced glycation end products (RAGE) is a part of immunoglobulin superfamily; it is believed to participate in ALS pathogenesis.
Our previous studies on ALS demonstrated that RAGE is likely one of the key players in ALS, acting on its own and in tandem with its oxidative stress and pro-inflammatory ligands, such as advanced glycation end products (AGEs) or advanced oxidation protein products (AOPPs). In this study, based on our previous results, we aimed to establish blood levels of soluble RAGE, AGE and AOPP in ALS patients.
Forty-six coded and anonymized surplus plasma samples from ALS patients and non-neurological control were used in the study. The plasma levels of RAGE, AGE and AOPP were measured using enzyme-linked immunosorbent assay (ELISA) commercially available kits. Statistical evaluation of data was performed using one-way non-parametric analysis of variance (ANOVA) with Kruskal-Wallis post hoc test.
Our results revealed a decline in soluble RAGE level, concurrent with an increase in the levels of AGEs and AOPPs in blood samples from ALS patients, signifying a loss of neuroprotective form of RAGE and a simultaneous increase in AGE and AOPP production and uptake at the early stage of the disease.
The results obtained from our study indicate that further longitudinal study of RAGE, AGE and AOPP levels would be beneficial, outlining the dynamics between RAGE and its ligand levels as the disease progresses, and making them valuable diagnostic tools and potential therapeutic targets.
肌萎缩侧索硬化症(ALS)是一种具有很大未知发病机制且无有效治疗方法的毁灭性神经退行性疾病。人们认为,有几种(并非相互排斥的)机制导致了这种疾病的发病机制和进展,包括氧化应激增加、兴奋性毒性、神经炎症增加和蛋白质聚集等。晚期糖基化终产物(AGEs)受体(RAGE)是免疫球蛋白超家族的一部分;它被认为参与了 ALS 的发病机制。
我们之前的 ALS 研究表明,RAGE 可能是 ALS 的关键参与者之一,它单独作用,也与氧化应激和促炎配体(如晚期糖基化终产物(AGEs)或高级氧化蛋白产物(AOPPs))一起作用。在这项研究中,根据我们之前的结果,我们旨在确定 ALS 患者血液中可溶性 RAGE、AGE 和 AOPP 的水平。
使用了 46 份编码和匿名的 ALS 患者和非神经控制患者的剩余血浆样本进行了这项研究。使用酶联免疫吸附测定(ELISA)试剂盒测量了 RAGE、AGE 和 AOPP 的血浆水平。使用单向非参数方差分析(ANOVA)和克鲁斯卡尔-沃利斯事后检验对数据进行了统计评估。
我们的结果显示,可溶性 RAGE 水平下降,同时 ALS 患者血液中的 AGEs 和 AOPPs 水平升高,这表明神经保护形式的 RAGE 丧失,同时在疾病早期 AGE 和 AOPP 的产生和摄取增加。
我们的研究结果表明,进一步对 RAGE、AGE 和 AOPP 水平进行纵向研究将是有益的,可以阐明 RAGE 与其配体水平随疾病进展的动态关系,使它们成为有价值的诊断工具和潜在的治疗靶点。